adult
relaps
refractori
bcell
acut
lymphoblast
leukemia
ball
poor
prognosi
keen
interest
explor
therapeut
modal
one
approach
genet
modifi
autolog
cell
express
chimer
antigen
receptor
car
target
specif
tumor
antigen
carmodifi
cell
target
b
cellspecif
antigen
studi
sever
clinic
trial
demonstr
high
rate
complet
remiss
patient
relaps
refractori
ball
base
encourag
result
car
tcell
product
recent
approv
us
food
drug
administr
treatment
relaps
refractori
ball
children
young
adult
number
advers
effect
associ
car
tcell
therapi
common
treatmentrel
toxic
effect
includ
cytokin
releas
syndrom
cr
neurolog
toxic
effect
cr
potenti
lifethreaten
condit
mediat
elev
proinflammatori
cytokin
includ
interleukin
coincid
car
tcell
expans
usual
occur
first
week
car
tcell
infus
cti
although
cr
success
manag
therapi
eg
tocilizumab
corticosteroid
clinic
present
cr
sepsi
often
indistinguish
thu
concomit
infect
cr
pose
diagnost
manag
challeng
fatal
howev
littl
known
frequenc
type
infecti
complic
car
tcell
therapi
whether
current
antimicrobi
prophylact
practic
suffici
furthermor
patient
increas
risk
prolong
bcell
aplasia
hypogammaglobulinemia
therapi
late
infecti
complic
car
tcell
therapi
remain
unknown
end
examin
infect
occur
within
first
day
adult
patient
relaps
refractori
ball
treat
car
cell
phase
clinic
trial
memori
sloan
ketter
cancer
center
mskcc
review
consecut
adult
relaps
refractori
ball
receiv
car
cell
mskcc
phase
clinic
trial
may
august
studi
complet
histor
cohort
studi
review
approv
institut
review
board
mskcc
detail
regard
studi
design
describ
elsewher
patient
underw
diseas
assess
bone
marrow
evalu
immedi
cti
studi
includ
stage
design
evalu
safeti
efficaci
dose
car
cell
kg
kg
addit
fludarabin
condit
chemotherapi
regimen
antimicrobi
prophylaxi
commenc
chemotherapi
continu
count
recoveri
need
switch
therapi
per
institut
guidelin
episod
infect
defin
presenc
clinic
symptom
along
corrobor
laboratori
radiograph
microbiolog
histopatholog
result
supplementari
materi
proven
probabl
invas
fungal
infect
ifi
defin
accord
publish
criteria
ifi
symptom
onset
occur
cti
exclud
timelin
document
infect
occur
day
cti
day
day
construct
patient
data
censor
receipt
allogen
hematopoiet
stem
cell
transplant
hsct
last
mskcc
followup
date
death
serial
serum
sampl
obtain
administr
condit
chemotherapi
cti
cytokin
profil
analyz
use
luminex
flexmap
system
commerci
avail
cytokin
detect
assay
describ
elsewher
data
extract
electron
medic
record
includ
demograph
prior
treatment
histori
hospit
intens
care
unit
length
stay
condit
chemotherapi
cti
antimicrobi
prophylaxi
subtyp
durat
leukopenia
antimicrobi
treatment
receiv
occurr
grade
cr
andor
neurotox
serum
immunoglobulin
g
igg
cytokin
level
diseas
respons
allogen
hsct
cti
surviv
neutropenia
defin
absolut
neutrophil
count
lymphopenia
absolut
lymphocyt
count
cr
defin
use
mskcc
grade
criteria
tabl
cr
grade
consid
mild
wherea
grade
consid
sever
describ
elsewher
neurotox
assess
accord
nation
cancer
institut
common
terminolog
criteria
advers
event
version
clinic
predictor
infect
assess
use
surviv
analysi
clinic
variabl
analyz
includ
age
sex
prior
line
chemotherapi
prior
allogen
hsct
condit
chemotherapi
morpholog
diseas
statu
blast
extramedullari
involv
car
tcell
dose
quantit
igg
nadir
maximum
cr
grade
cox
proport
hazard
model
use
examin
potenti
predictor
variabl
first
analyz
individu
mean
univari
analysi
cr
analyz
timedepend
predictor
predictor
univari
p
valu
analyz
multivari
model
kaplanmei
plot
use
estim
associ
cr
grade
infect
statist
analys
perform
use
r
softwar
version
r
develop
core
team
fiftythre
patient
relaps
refractori
ball
receiv
car
cell
studi
period
detail
patient
laboratori
characterist
list
tabl
median
age
year
interquartil
rang
iqr
year
men
major
white
studi
patient
pretreat
median
prior
line
chemotherapi
iqr
cti
patient
underw
prior
allogen
hsct
per
protocol
receiv
condit
chemotherapi
either
cyclophosphamid
alon
n
cyclophosphamid
plu
fludarabin
n
cyclophosphamid
plu
clofarabin
n
condit
chemotherapi
document
absolut
lymphocyt
count
median
lymphopenia
durat
day
iqr
day
absolut
neutrophil
count
median
neutropenia
among
treat
patient
complet
remiss
achiev
cr
grade
occur
patient
sever
cr
defin
grade
occur
includ
patient
grade
cr
develop
die
multiorgan
failur
day
treatment
cr
manag
tocilizumab
n
tocilizumab
plu
corticosteroid
n
corticosteroid
alon
n
support
care
patient
n
grade
neurotox
observ
patient
respect
case
cerebr
edema
fatal
neurolog
event
twenti
patient
transfer
intens
care
unit
closer
monitor
symptom
relat
cr
andor
neurotox
detail
antimicrobi
prophylaxi
list
tabl
none
receiv
fluoroquinolon
prophylaxi
patient
receiv
antivir
prophylaxi
receiv
antipneumocysti
prophylaxi
fortytwo
patient
given
antifung
prophylaxi
micafungin
mgd
intraven
frequent
prescrib
agent
first
day
cti
infect
develop
patient
infect
occur
patient
neutropen
tabl
figur
bacteri
infect
predomin
includ
bloodstream
infect
bsi
intraabdomin
infect
case
clostridium
difficil
diarrhea
pneumonia
case
pyelonephr
chest
wall
abscess
four
ifi
occur
patient
receiv
micafungin
prophylaxi
includ
case
saccharomyc
cerevisia
fungemia
probabl
invas
pulmonari
aspergillosi
proven
pulmonari
mucormycosi
viral
reactiv
herp
simplex
varicella
zoster
viru
case
shingl
occur
absenc
acyclovir
prophylaxi
three
viral
upper
respiratori
tract
infect
round
remain
infect
twentyfour
surviv
patient
attain
complet
remiss
igg
level
check
day
receipt
hsct
relaps
last
mskcc
followup
whichev
date
came
first
patient
low
igg
level
median
mgdl
iqr
patient
receiv
intraven
immunoglobulin
ten
patient
infect
day
day
includ
viral
respiratori
virus
bk
viruria
bacteri
fungal
infect
tabl
figur
patient
hypogammaglobulinem
three
patient
die
infecti
complic
studi
period
patient
longstand
histori
pneumonia
tracheostomi
cti
die
necrot
pneumonia
septicemia
due
multidrugresist
pseudomona
antimicrobi
prophylaxi
cti
aeruginosa
day
cti
patient
undergon
prior
allogen
hsct
die
polymicrobi
sepsi
day
cti
analyz
variou
preand
posttreat
clinic
factor
examin
associ
increas
infecti
risk
wherea
age
sex
prior
line
chemotherapi
prior
allogen
hsct
cyclophosphamid
dose
condit
regimen
cyclophosphamid
alon
vs
cyclophosphamid
plu
fludarabin
diseas
burden
car
tcell
dose
hypogammaglobulinemia
correl
risk
infect
univari
analysi
cr
grade
associ
increas
risk
subsequ
infect
particularli
bsi
figur
demonstr
signific
associ
highgrad
cr
risk
infect
examin
whether
serum
cytokin
profil
differ
patient
cr
infect
first
identifi
serum
cytokin
correl
grade
cr
interferon
interleukin
tumor
necrosi
factor
supplementari
figur
compar
serum
cytokin
panel
patient
cr
infect
patient
found
differ
serum
level
supplementari
figur
consid
time
infect
organ
type
bacteri
infect
occur
median
day
iqr
cti
follow
fungal
infect
median
day
iqr
day
viral
infect
median
day
iqr
day
studi
highlight
frequenc
type
sever
infecti
complic
patient
relaps
refractori
ball
first
month
car
tcell
therapi
overal
patient
experienc
infect
predominantli
bacteri
within
first
day
cti
patient
complet
remiss
experienc
infect
mani
due
respiratori
viru
day
infectionrel
mortal
rate
low
heavili
treat
patient
death
occur
case
either
multidrugresist
organ
n
polymicrobi
infect
n
recent
public
earli
day
late
day
infecti
complic
seen
patient
underw
car
tcell
therapi
respect
although
direct
comparison
limit
differ
method
period
observ
type
infect
occur
earli
late
period
cti
similar
studi
lifethreaten
fatal
infect
also
rare
found
presenc
grade
cr
factor
independ
associ
infect
particular
bsi
unclear
whether
tocilizumab
corticosteroid
use
treat
highgrad
cr
increas
risk
infect
independ
cr
abl
find
signific
associ
univari
analysi
data
shown
notabl
similar
find
associ
cr
infect
recent
report
anoth
trial
car
cell
differ
costimulatori
domain
vs
studi
patient
chronic
lymphocyt
leukemia
nonhodgkin
lymphoma
howev
potenti
mechan
underli
associ
highgrad
cr
infect
unclear
although
highgrad
cr
correl
robust
car
tcell
expans
preclin
studi
demonstr
tonic
car
signal
may
induc
earli
exhaust
cell
current
evid
suggest
cell
lead
immun
dysfunct
sepsi
due
infect
trigger
cytokin
storm
potenti
lead
higher
proinflammatori
cytokin
patient
cr
due
cti
examin
cytokin
profil
patient
experienc
cr
without
document
infect
found
although
cytokin
level
correspond
sever
cr
pattern
differ
patient
cr
without
concomit
infect
find
suggest
unlik
infect
exacerb
cr
alter
cytokin
level
studi
requir
investig
whether
high
level
proinflammatori
antiinflammatori
g
sputi
bsi
cytokin
immunosuppress
therapi
contribut
increas
risk
infect
patient
sever
cr
nonetheless
infect
occur
togeth
time
cr
clinician
awar
infecti
complic
sign
symptom
cr
sepsi
often
difficult
distinguish
differ
manag
eg
use
therapi
corticosteroid
cr
date
standard
antimicrobi
prophylact
practic
patient
undergo
cti
ball
howev
made
sever
observ
first
studi
found
case
pneumocysti
jiroveci
pneumon
rare
herpet
viral
reactiv
nearli
viral
infect
due
respiratori
virus
occur
late
cti
median
day
also
observ
bacteri
infect
occur
median
day
cti
follow
fungal
infect
median
day
earli
occurr
bacteri
infect
follow
fungal
infect
mirror
patient
undergo
allogen
hsct
highrisk
patient
acut
leukemia
myelodysplast
syndrom
receiv
cytotox
chemotherapi
although
studi
patient
receiv
fluoroquinolon
prophylaxi
car
tcell
therapi
debat
whether
fluoroquinolon
prophylaxi
would
signific
util
particular
cohort
c
difficil
infect
exclud
found
remain
document
bacteri
infect
diagnos
within
first
day
cti
due
resist
organ
includ
vre
esblproduc
escherichia
coli
multidrugresist
p
aeruginosa
carbapenemaseproduc
klebsiella
pneumonia
infect
studi
patient
previous
experienc
line
chemotherapi
ball
patient
also
undergon
prior
allogen
hsct
thu
infer
patient
signific
antimicrobi
exposur
car
tcell
therapi
although
prior
antimicrobi
exposur
wellknown
risk
factor
colon
resist
organ
difficult
know
degre
contribut
studi
cohort
decis
regard
choic
antifung
prophylaxi
depend
sever
factor
includ
local
epidemiolog
drug
interact
advers
effect
profil
mskcc
breakthrough
ifi
among
patient
receiv
antifung
prophylaxi
major
patient
receiv
micafungin
prophylaxi
mg
intraven
daili
compar
posaconazol
suspens
micafungin
associ
lower
rate
prematur
discontinu
gastrointestin
intoler
advers
effect
patient
acut
leukemia
myelodysplast
syndrom
singlecent
random
openlabel
studi
although
breakthrough
ifi
occur
patient
receiv
micafungin
find
compar
rate
proven
probabl
ifi
micafungin
prophylact
arm
remain
seen
whether
patient
undergo
car
tcell
therapi
better
stratifi
identifi
higher
risk
invas
mold
infect
better
target
antifung
prophylaxi
prolong
bcell
aplasia
known
complic
target
therapi
look
infect
consist
humor
immun
defici
eg
recurr
sinopulmonari
infect
diarrhea
evalu
hypogammaglobulinemia
surviv
model
howev
patient
igg
level
avail
hypogammaglobulinemia
mild
obviat
need
routin
immunoglobulin
replac
although
see
clear
exampl
humor
immun
defici
number
examin
patient
n
small
rate
degre
durat
bcell
aplasia
hypogammaglobulinemia
may
vari
depend
patient
age
children
vs
adult
durat
car
tcell
persist
therefor
may
requir
prospect
evalu
although
car
tcell
therapi
may
impart
addit
infecti
risk
explain
patient
backdrop
prior
cancer
treatment
possibl
quantifi
attribut
risk
part
owe
difficulti
select
appropri
comparison
group
highli
custom
patient
cohort
particip
phase
clinic
trial
singlecent
studi
epidemiolog
infect
along
suscept
pattern
may
differ
center
thu
may
affect
one
institut
approach
antimicrobi
prophylaxi
summari
infect
common
adult
relaps
ball
car
tcell
therapi
cooccur
time
cr
although
infectionrel
death
low
base
observ
frequenc
time
infect
antimicrobi
prophylaxi
probabl
parallel
highrisk
neutropen
patient
although
local
bacteri
fungal
epidemiolog
consid
gain
experi
differ
car
construct
variou
hematolog
cancer
studi
conduct
better
understand
acut
delay
infecti
complic
order
develop
optim
prophylact
manag
strategi
improv
clinic
outcom
patient
variou
hematolog
cancer
receiv
car
cell
supplementari
materi
avail
clinic
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
potenti
conflict
interest
j
h
p
report
connect
amgen
consultingadvisori
role
juno
therapeut
research
fund
genentechroch
research
fund
pfizer
consultingadvisori
role
r
j
b
report
connect
juno
therapeut
consultingadvisori
role
royalti
share
agreement
stock
ownership
research
fund
r
j
b
author
report
potenti
conflict
interest
author
submit
icmj
form
disclosur
potenti
conflict
interest
conflict
editor
consid
relev
content
manuscript
disclos
